Giampaolo Bianchini

Profession:
Oncologist
Languages:
EN
IT

Biography

Dr. Giampaolo Bianchini is the Head of the Department Breast Cancer of the Department of Medical Oncology of the Ospedale San Raffaele Clinical Research Institute, headed by Professor Stefano Cascinu.

After graduating in 2000 from the Faculty of Medicine and Surgery of the University of Milan Bicocca, he completed his specialization in Medical Oncology at the University of Milan in 2004. During his studies, he was a visiting specialist at various prestigious American institutions such as the National Cancer Institute (Bethesda), MD Anderson Cancer Center (Houston) and Yale Cancer Center (New Haven).

Dr. Bianchini has been treating patients with early and metastatic breast carcinoma with nearly twenty years of clinical experience. In addition, he has a particular interest in the development of new therapies and immunotherapeutic approaches for the treatment of breast carcinoma.

Giampaolo Bianchini is also a Team Leader for Immunotherapy and Translational Clinical Research at the Department of Medical Oncology and is involved in numerous research projects for women with breast carcinoma to understand the response mechanisms and resistance to existing drugs, identify new therapeutic strategies, and identify biomarkers which help to choose an individual treatment.

In addition, he is involved in studies to identify the mechanisms of response and resistance to immunotherapeutic drugs, as well as in the development of clinical trials for their use in the treatment of breast carcinoma and many other solid tumors.

Dr. Bianchini is the author of numerous publications in international journals such as the Journal Clinical Oncology, Lancet Oncology, Cancer Cell, Journal National Cancer Institute, JAMA Oncology and Annals of Oncology. Its H index is 22. He regularly participates in national and international congresses and symposia.

Read moreRead less

Education

University of Milan Bicocca

Degree in Medicine and Surgery – 2000

University of Milan Bicocca

Medical Oncology Specialization – 2004

Do you need an appointment?

Contact us and we will take care of you.

Publications

Dr. Bianchini is the author of numerous publications in international journals such as the Journal Clinical Oncology, Lancet Oncology, Cancer Cell, Journal National Cancer Institute, JAMA Oncology and Annals of Oncology. Its H index is 22. He regularly participates in national and international congresses and symposia.

Latest publications

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
J Clin Oncol 28:4316-23, 2010
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
Cancer Res 70:8852-62, 2010
Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang C, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WK, Gianni L, Pusztai L.
Read more
Biological processes associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
J Natl Cancer Inst 2010 Dec 29
Iwamoto T, Bianchini G, Booser D, QI Y, Coutant C, Shiang C, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes F, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai
Read more
Breast cancer genomics: challenges in interpretation and application.
Oncologist. 2013;18(4):e11-2
Kelly CM, Symmans WF, Andreopoulou E, Bianchini G
Read more
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.
Breast Cancer Research 2013 15:R86
Bianchini G*, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Muller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Angelica F, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L
Read more
An unmeet need: tailoring extended adjuvant endocrine therapy
British Journal of Cancer (2013), 1–4
Bianchini G, Gianni L
Read more
The immune system and response to her2-targeted therapy in breast cancer.
The Lancet Oncology (2014) 15:e58-e68
Bianchini G, Gianni L
Read more
Research-based pam50 subtype predictor identifies higher responses and improved survival outcomes in her2-positive breast cancer in the noah study.
Clin Cancer Res (2014) 20:511-21, 2014
Prat A, Bianchini G, Thomas M, Belousov A, Cheang MCU, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez V, Gianni L, Baselga J
Read more
Immune modulation of pathologic complete response after neoadjuvant her2-directed therapies in the neosphere trial.
Annals of Oncology 26(12): 2429-36
Bianchini G, Pusztai L, Pienkowski T, Im Y-H, Bianchi GV, Tseng L-M, Liu M-C, Lluch A, Galeota E, Magazzù D, Rodríguez J, Oh D-Y, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L
Read more
Subtype specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer.
Clinical Cancer Research 22(2): 337-45
Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, Bianchini G*
Read more
New strategies in breast cancer: immunotherapy.
Clin Cancer Res 22(9): 2105-10
Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G
Read more
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Nat Rev Clin Oncol Nov;13(11):674-690.
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L
Read more
Biomarker analysis of the neosphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of her2-positive breast cancer.
Breast Cancer Res 19(1): 16
Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L
Read more
Association between genomic metrics and immune infiltration in triple-negative breast cancer.
JAMA Oncology (doi:10.1001/jamaoncol.2017.2140)
Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L
Read more
Is trastuzumab single agent obsolete in eraly breast cancer? No.
Breast. 2019 Feb;43:142-145
Bianchini G
Read more

Do you need an appointment?

Contact us and we will take care of you.